The oncologist · 2026
Understanding the symptoms and impacts of living with metastatic pancreatic adenocarcinoma: a prospective, noninterventional qualitative study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Oh Mok, Chang Lawrence, Matney Cassandra, Fuldeore Rupali, Perez Eyra, Alici Yesne, Buzaglo Joanne, Mao Michelle, Park Wungki
Аннотация
BACKGROUND: The symptom burden associated with advanced pancreatic cancer, such as metastatic pancreatic adenocarcinoma (mPC), reduces patients' health-related quality of life (HRQoL). Recognizing the impact of disease- and treatment-related symptoms is essential in refining patient-reported outcomes (PROs) in clinical research, ensuring that PRO measures in clinical trials support US Food and Drug Administration label statements, and improving patient HRQoL.
PATIENTS AND METHODS: Patients with mPC and caregivers of patients with mPC were interviewed for this qualitative study. Insights from interviews were used to update a preliminary conceptual model derived from a targeted literature review. The primary objective was to obtain an in-depth understanding of patients' experience of living with mPC and the impact of mPC on patients' lives.
RESULTS: Across 19 interviews (n = 16 patients, n = 3 caregivers), the most frequently reported symptoms were tiredness (n = 19); fatigue, nausea, and weight loss (n = 18 each); and diarrhea and hair loss/thinning (n = 16 each); 17 participants reported mPC- and/or treatment-related pain. The most frequently reported impacts were anxiety (n = 17), reduced physical functioning (n = 16), and worry/fear of disease (n = 16). After identification of the most salient symptoms and impacts, two symptoms and four impacts were added to the preliminary conceptual model and 31 symptoms and 11 impacts were removed to generate the final conceptual model (40 symptoms and 26 impacts).
CONCLUSION: This qualitative interview study uncovered previously unreported symptoms and impacts of mPC and supports the careful selection of appropriate PRO measures that more comprehensively reflect the experience of patients with mPC in future clinical trials.
PATIENTS AND METHODS: Patients with mPC and caregivers of patients with mPC were interviewed for this qualitative study. Insights from interviews were used to update a preliminary conceptual model derived from a targeted literature review. The primary objective was to obtain an in-depth understanding of patients' experience of living with mPC and the impact of mPC on patients' lives.
RESULTS: Across 19 interviews (n = 16 patients, n = 3 caregivers), the most frequently reported symptoms were tiredness (n = 19); fatigue, nausea, and weight loss (n = 18 each); and diarrhea and hair loss/thinning (n = 16 each); 17 participants reported mPC- and/or treatment-related pain. The most frequently reported impacts were anxiety (n = 17), reduced physical functioning (n = 16), and worry/fear of disease (n = 16). After identification of the most salient symptoms and impacts, two symptoms and four impacts were added to the preliminary conceptual model and 31 symptoms and 11 impacts were removed to generate the final conceptual model (40 symptoms and 26 impacts).
CONCLUSION: This qualitative interview study uncovered previously unreported symptoms and impacts of mPC and supports the careful selection of appropriate PRO measures that more comprehensively reflect the experience of patients with mPC in future clinical trials.